《新股消息》未盈利生科企業派格生物申請主板上市
未盈利生物科技企業派格生物申請於聯交所主板上市,由中金公司擔任獨家保薦人。
初步招股文件顯示,派格生物為專注於自主研究及開發慢性病創新療法的生物技術公司,目前已自主開發一款核心產品及其他五款候選產品,用於治療2型糖尿病(T2DM)、肥胖症、非酒精性脂肪性肝炎(NASH)、阿片類藥物引起的便秘(OIC)及先天性高胰島素血症等常見慢病及代謝疾病。
其中核心產品PB-119接近商業化階段,用於治療T2DM的新藥上市申請已於去年9月獲國家藥監局受理,公司有計劃在全球範圍內推進PB-119的商業化。
派格生物表示,目前沒有任何商業化產品,截至去年9月底止首三季錄虧損2.25億元人民幣,對比2022年同期虧損為2.36億元人民幣。預期上市集資所得將用於核心產品PB-119的商業化和適應症拓展;用以資助主要產品PB-718的進一步開發;資助其他管線候選產品的持續及計劃研究和開發;以及用於業務發展活動及加強全球網絡等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.